Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.65 |
| ▸ | GRM6 | O15303 | 1/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.65 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.65 |
| ▸ | GSR | P00390 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.65 |
| ▸ | GRM5 | P41594 | 1/20 | 0.65 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.65 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.65 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.65 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.65 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.65 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.65 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.65 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.65 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.65 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.65 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.65 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950889 | 0.82 | GSR (0.42) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL27876599 | 0.80 | ALOX15 (0.62) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL27876596 | 0.80 | ALOX15 (0.62) | GRM8GRM6GRIN2DGRIN3BGSR | |
| D-Glutamate SCHEMBL17127348 | 0.79 | GRM8 (1.00) | GRM8GRM6GRIN2DGRIN3BGSR | |
| D-Glutamate SCHEMBL1330824 | 0.79 | GRM8 (1.00) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL25384088 | 0.79 | CYP1A2 (0.71) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Glutamic Acid SCHEMBL1554237 | 0.79 | GRM8 (1.00) | GRM8GRM6GRIN2DGRIN3BGSR | |
| D-Glutamate SCHEMBL1330484 | 0.79 | GRM8 (1.00) | GRM8GRM6GRIN2DGRIN3BGSR | |
| Glutamic Acid SCHEMBL248800 | 0.79 | GRM8 (1.00) | GRM8GRM6GRIN2DGRIN3BGSR | |
| D-Glutamate SCHEMBL2201 | 0.79 | GRM8 (1.00) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218010-A1 | Methods of Producing Sulfated Oligosaccharide Derivatives and Intermediates Thereof | PROGEN PG500 SERIES PTY LTD (AU) | 2024-07-04 | — | — | US | disclosed |
| CN-116589612-A | Pyridyl cationic sugar-containing polymer and preparation method and application thereof | 西华大学 | 2023-08-15 | — | — | CN | disclosed |
| EP-0809314-B1 | Positive active material, method of manufacturing and secondary battery using the same | CANON KK (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-0600718-B1 | Secondary battery | CANON KK (JP) | 2000-04-26 | — | — | EP | disclosed |
| EP-0809314-A2 | Positive active material, method of manufacturing and secondary battery using the same | CANON KABUSHIKI KAISHA (JP) | 1997-11-26 | — | — | EP | disclosed |
| EP-0600718-A2 | Secondary battery | CANON KABUSHIKI KAISHA (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218010-A1 | Methods of Producing Sulfated Oligosaccharide Derivatives and Intermediates Thereof | OSTC, FUT5, NPY5R | GRM8 2104/4885GRM6 1070/4885GRIN2D 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.